Actavis launches generic Catapres-TTS

DUBLIN — Actavis announced that it has launched a generic version of Boehringer Ingelheim's Catapres-TTS (clonidine transdermal system, USP, 0.1-mg/day, 0.2-mg/day, and 0.3-mg/day for one week), following the company's final approval on its abbreviated new drug application from the Food and Drug Administration.

Catapres-TTS is used for the treatment of hypertension. The drug had total U.S. sales of approximately $180 million for the 12 months ending Feb. 28, 2014, according to IMS Health.


Login or Register to post a comment.